Resolution of the Expert council on current issues of prescribing clotting factor VIII with prolonged half-life (INN — Efmoroctocog alfa) in patients with hemophilia A
https://doi.org/10.21682/2311-1267-2021-8-2-142-143
Abstract
В ходе Совета экспертов, который состоялся 11 мая 2021 г., обсуждались критерии назначения препарата фактора свертывания крови VIII (эфмороктоког альфа) с пролонгированным периодом полувыведения пациентам с гемофилией А.
References
1. Instructions for the medical use of the drug Eloctate (Efmoroctocog alpha) LP-006034. [Electronic resource]: https://grls.rosminzdrav.ru/GRLS.aspx (appeal date 17.08.2020). (In Russ.).
2. McCue J., Kshirsagar R., Selvitelli K., Lu Q., Zhang M., Mei B., Peters R., Pierce G.F., Dumont J., Raso S., Reichert H. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals 2015;43(4):213-9. doi: 10.1016/j.biologicals.2015.05.012.
3. Rath T., Baker K., Dumont J.A., Peters R.T., Jiang H., Qiao S.-W., Lencer W.I., Pierce G.F., Blumberg R.S. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2015;35(2):235-54. doi: 10.3109/07388551.2013.834293.
4. Powell J.S., Josephson N.C., Quon D., Ragni M.V., Cheng G., Li E., Jiang H., Li L., Dumont J.A., Goyal J., Zhang X., Sommer J., McCue J., Barbetti M., Luk A., Pierce G.F. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in haemophilia A patients. Blood 2012;119(13):3031-7. doi: 10.1182/blood-2011-09-382846.
5. Young G., Mahlangu J., Kulkarni R., Nolan B., Liesner R., Pasi J., Barnes C., Neelakantan S., Gambino G., Cristiano L.M., Pierce G.F., Allen G. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015;13(6):967-77. doi: 10.1111/jth.12911.
6. Nolan B., Mahlangu J., Pabinger I., Young G., Konkle B.A., Barnes C., Nogami K., Santagostino E., Pasi K.J., Khoo L., Winding B., Yuan H., Fruebis J., Rudin D., Oldenburg J. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia 2020;26(3):494-502. doi: 10.1111/hae.13953.
7. Konigs C., Ozelo M.C., Dunn A., Kulkarni R., Nolan B., Brown S.A., Liesner R., Schiavulli M., Gunawardena S., Mukhopadhyay S., Jayawardene D., Winding B., Carcao M. Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A (abstr.). Res Pract Thromb Haemost 2020;4(Suppl 1).
8. Wyrwich K.W., Krishnan S., Auguste P., Poon J.-L., von Maltzahn R., Yu R., Pierce G.F., Mei B., Mahlangu J., von Mackensen S. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia 2016;22(6):866-72. doi: 10.1111/hae.12987.
Review
For citations:
Resolution of the Expert council on current issues of prescribing clotting factor VIII with prolonged half-life (INN — Efmoroctocog alfa) in patients with hemophilia A. Russian Journal of Pediatric Hematology and Oncology. 2021;8(2):142-143. (In Russ.) https://doi.org/10.21682/2311-1267-2021-8-2-142-143
Views:
604
Email this article 